[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mediastinal-and-hilar-lymph-node-enlargement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mediastinal-and-hilar-lymph-node-enlargement":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100628279","diagnostic-performance-and-safety-of-endobronchial-ultrasound-guided-transbronchial-mediastinal-cryobiopsy-in-diagnosing-tuberculous-mediastinal-lymphadenitis-a-randomised-controlled-trial-100628279",false,"NCT07459569","Diagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older;\n* Presence of unexplained mediastinal lymphadenopathy (short-axis diameter ≥1 cm on chest computed tomography) with clinical suspicion of tuberculosis;\n* Completion of routine pre-procedural evaluations including blood tests (complete blood count, coagulation profile), electrocardiogram, and chest CT;\n* Absence of contraindications for EBUS-TBNA or EBUS-TBMC procedures;\n* Provision of written informed consent after being fully informed of the study purpose and procedures.\n\nExclusion Criteria:\n\n* Known allergy to lidocaine or midazolam;\n* Presence of bronchial artery penetration into the target lesion or high risk of bleeding as detected by contrast-enhanced CT or EBUS Doppler mode prior to the procedure;\n* Unstable angina, congestive heart failure, or severe bronchial asthma;\n* Evidence of significant liquefaction necrosis in the target mediastinal lymph node on pre-procedural CT or EBUS;\n* Patient refusal to participate in the study;\n* Participation in another clinical trial within the past three months that may interfere with the outcomes of this study;\n* Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study participation","ALL","18 Years",{"count":18,"type":19},108,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to compare the diagnostic efficacy and safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy (EBUS-TBMC) versus standard EBUS-guided Transbronchial Needle Aspiration (EBUS-TBNA) in adult patients with suspected mediastinal lymph node tuberculosis. The main questions it aims to answer are:\n\nDoes EBUS-TBMC provide a superior diagnostic yield for detecting granulomatous inflammation compared to EBUS-TBNA in the same target lymph node? Does the cryopreservation process affect the viability of Mycobacterium tuberculosis for culture, and does the larger tissue sample obtained via EBUS-TBMC enhance the sensitivity of molecular tests such as Xpert MTB\u002FRIF? Is the safety profile of EBUS-TBMC, particularly regarding bleeding complications, comparable to that of EBUS-TBNA in this patient population? Researchers will compare the two biopsy techniques using a paired design within the same patient to see if EBUS-TBMC results in higher rates of positive pathology, microbiology, and molecular diagnoses.\n\nParticipants will:\n\nUndergo both EBUS-TBNA and EBUS-TBMC procedures on the same mediastinal lymph node during a single bronchoscopy session, with the order of procedures randomized.\n\nProvide blood and tissue samples for comprehensive testing, including histology, mycobacterial culture, and Xpert MTB\u002FRIF assay.\n\nComplete short-term (within 2 hours post-procedure) and 7-day follow-up assessments to monitor for any adverse events.\n\nParticipate in a 6-month clinical follow-up to establish a final diagnosis, which will serve as the reference standard for evaluating the diagnostic tests.",[25,26],"Tuberculosis","Mediastinal and Hilar Lymph Node Enlargement","NOT_YET_RECRUITING","2026-03-05",{"date":30,"type":31},"2026-03-09","ACTUAL",{"date":33,"type":19},"2026-05",{"date":35,"type":19},"2027-05",{"name":37,"class":38},"China-Japan Friendship Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100597583","a-study-of-contrast-enhanced-ebus-in-lung-lesions-and-intrathoracic-lymph-nodes-100597583","NCT07060378","A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes","Inclusion Criteria:\n\n* Age \\>18 years old；\n* Enlargement of at least one intrathoracic LN (short diameter \\> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET \u002F CT (standardized uptake value \\> 2.5)；\n* CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;\n* Patients who have good compliance and sign informed consent.\n\nExclusion Criteria:\n\n* Patients with known hypersensitivity to ultrasound contrast components;\n* Patients with severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg);\n* Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;\n* Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;\n* Pregnant or lactating women；\n* Patients with contraindications to bronchoscopy；\n* Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.","90 Years",{"count":48,"type":19},250,[22],"Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes",[52,26],"Lung Lesions",[54,55,56],"CE-EBUS","Ultrasound Contrast Agent","Microbubbles","RECRUITING","2025-07-10",{"date":60,"type":31},"2025-07-11",{"date":58,"type":31},{"date":63,"type":19},"2026-01-30",{"name":65,"class":38},"Shanghai Chest Hospital"]